# OnCo record prodige-4-accord-11 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/prodige-4-accord-11/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "prodige-4-accord-11", "NCT00112658" ;
  schema:name "PRODIGE 4 / ACCORD 11"@en ;
  schema:alternateName "PRODIGE 4"@en, "ACCORD 11"@en, "PRODIGE4-ACCORD11"@en, "FOLFIRINOX versus gemcitabine"@en ;
  schema:description "PRODIGE 4 is the 2011 French trial that changed pancreatic cancer treatment for the first time in fourteen years: the four-drug FOLFIRINOX combination kept fit patients alive a median 11.1 months against 6.8 with gemcitabine, at the price of more side effects, and it remains the reference first-line regimen for people well enough to have it."@en ;
  schema:url <https://onco.cc/trials/prodige-4-accord-11/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00112658>, <https://doi.org/10.1056/NEJMoa1011923> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/leucovorin/> ;
  onco:companies <https://onco.cc/companies/unicancer/> ;
  onco:terms <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/quality-of-life/> ;
  onco:people <https://onco.cc/people/thierry-conroy/> .